Bacteriophage-based synthetic biology for the study of infectious diseases

Current Opinion in Microbiology

Volumn 19, Issue 1, 2014, Pages 59-69

  Citorik, Robert J ^a,b   Mimee, Mark ^a,b   Lu, Timothy K ^a,b,c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC SENSITIVITY; BACTERIOPHAGE; EVOLUTION; GENOME MINING; GENOMIC INSTABILITY; INFECTION; MICROORGANISM DETECTION; MINING; NONHUMAN; PHAGE DISPLAY; REVIEW; SYNTHETIC BIOLOGY; COMMUNICABLE DISEASE; RESEARCH; TRENDS;

BACTERIOPHAGES; COMMUNICABLE DISEASES; RESEARCH; SYNTHETIC BIOLOGY;

EID: 84903647612     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2014.05.022     Document Type: Review

References (128)

1. Twort F.W. An investigation on the nature of ultra-microscopic viruses. Lancet 1915, 186:1241-1243.
2. D'Hérelle F. Sur un microbe invisible antagoniste des bacilles dysentérique. C R Acad Sci 1917, 165:373-375.
3. Bruynoghe R., Maisin J. Essais de thérapeutique au moyen du bacteriophage. C R Soc Biol 1921, 85:1120-1121.
4. Summers W.C. Bacteriophage therapy. Annu Rev Microbiol 2001, 55:437-451.
5. Fruciano D.E., Bourne S. Phage as an antimicrobial agent: d'Herelle's heretical theories and their role in the decline of phage prophylaxis in the West. Can J Infect Dis Med Microbiol 2007, 18:19-26.
6. Summers W.C. The strange history of phage therapy. Bacteriophage 2012, 2:130-133.
7. Henry M., Debarbieux L. Tools from viruses: bacteriophage successes and beyond. Virology 2012, 434:151-161.
8. Barrow P.A., Soothill J.S. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol 1997, 5:268-271.
9. Kutateladze M., Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 2010, 28:591-595.
10. Lu T.K., Koeris M.S. The next generation of bacteriophage therapy. Curr Opin Microbiol 2011, 14:524-531.
11. Gravitz L. Turning a new phage. Nat Med 2012, 18:1318-1320.
12. Carlton R.M. Phage therapy: past history and future prospects. Arch Immunol Ther Exp (Warsz) 1999, 47:267-274.
13. Sulakvelidze A., Alavidze Z., Morris J.G. Bacteriophage therapy. Antimicrob Agents Chemother 2001, 45:649-659.
14. Merril C.R., Scholl D., Adhya S.L. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2003, 2:489-497.
15. Abedon S.T., Kuhl S.J., Blasdel B.G., Kutter E.M. Phage treatment of human infections. Bacteriophage 2011, 1:66-85.
16. Slusarczyk A.L., Lin A., Weiss R. Foundations for the design and implementation of synthetic genetic circuits. Nat Rev Genet 2012, 13:406-420.
17. Lu T.K., Khalil A.S., Collins J.J. Next-generation synthetic gene networks. Nat Biotechnol 2009, 27:1139-1150.
18. Cheng A.A., Lu T.K. Synthetic biology: an emerging engineering discipline. Annu Rev Biomed Eng 2012, 14:155-178.
19. Brophy J.A.N., Voigt C.A. Principles of genetic circuit design. Nat Methods 2014, 11:508-520.
20. Elowitz M.B., Leibler S. A synthetic oscillatory network of transcriptional regulators. Nature 2000, 403:335-338.
21. Gardner T.S., Cantor C.R., Collins J.J. Construction of a genetic toggle switch in Escherichia coli. Nature 2000, 403:339-342.
22. Siuti P., Yazbek J., Lu T.K. Synthetic circuits integrating logic and memory in living cells. Nat Biotechnol 2013, 31:448-452.
23. Bonnet J., Yin P., Ortiz M.E., Subsoontorn P., Endy D. Amplifying genetic logic gates. Science 2013, 340:599-603.
24. Paddon C.J., Westfall P.J., Pitera D.J., Benjamin K., Fisher K., McPhee D., Leavell M.D., Tai A., Main A., Eng D., et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 2013, 496:528-532.
25. Saeidi N., Wong C.K., Lo T.-M., Nguyen H.X., Ling H., Leong S.S.J., Poh C.L., Chang M.W. Engineering microbes to sense and eradicate Pseudomonas aeruginosa, a human pathogen. Mol Syst Biol 2011, 7:521.
26. Xie Z., Wroblewska L., Prochazka L., Weiss R., Benenson Y. Multi-input RNAi-based logic circuit for identification of specific cancer cells. Science 2011, 333:1307-1311.
27. Galloway K.E., Franco E., Smolke C.D. Dynamically reshaping signaling networks to program cell fate via genetic controllers. Science 2013, 341:1235005.
28. Ye H., Charpin-El Hamri G., Zwicky K., Christen M., Folcher M., Fussenegger M. Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. Proc Natl Acad Sci U S A 2013, 110:141-146.
29. Moon T.S., Lou C., Tamsir A., Stanton B.C., Voigt C.A. Genetic programs constructed from layered logic gates in single cells. Nature 2012, 491:249-253.
30. Ausländer S., Ausländer D., Müller M., Wieland M., Fussenegger M. Programmable single-cell mammalian biocomputers. Nature 2012, 487:123-127.
31. Daniel R., Rubens J.R., Sarpeshkar R., Lu T.K. Synthetic analog computation in living cells. Nature 2013, 497:619-623.
32. Ruder W.C., Lu T., Collins J.J. Synthetic biology moving into the clinic. Science 2011, 333:1248-1252.
33. Keasling J.D. Synthetic biology and the development of tools for metabolic engineering. Metab Eng 2012, 14:189-195.
34. Roquet N., Lu T.K. Digital and analog gene circuits for biotechnology. Biotechnol J 2014, 9:597-608.
35. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228:1315-1317.
36. Jacobsson K., Frykberg L. Phage display shot-gun cloning of ligand-binding domains of prokaryotic receptors approaches 100% correct clones. Biotechniques 1996, 20:1070-1076. 1078, 1080-1081.
37. Jönsson K., Guo B.P., Monstein H.-J., Mekalanos J.J., Kronvall G. Molecular cloning and characterization of two Helicobacter pylori genes coding for plasminogen-binding proteins. Proc Natl Acad Sci U S A 2004, 101:1852-1857.
38. Bazan J., Całkosiński I., Gamian A. Phage display-a powerful technique for immunotherapy: 2. Vaccine delivery. Hum Vaccin Immunother 2012, 8:1829-1835.
39. Basha S., Rai P., Poon V., Saraph A., Gujraty K., Go M.Y., Sadacharan S., Frost M., Mogridge J., Kane R.S. Polyvalent inhibitors of anthrax toxin that target host receptors. Proc Natl Acad Sci U S A 2006, 103:13509-13513.
40. Paradis-Bleau C., Lloyd A., Sanschagrin F., Clarke T., Blewett A., Bugg T.D.H., Levesque R.C. Phage display-derived inhibitor of the essential cell wall biosynthesis enzyme MurF. BMC Biochem 2008, 9:33.
41. Frenzel A., Kügler J., Wilke S., Schirrmann T., Hust M. Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol Biol 2014, 1060:215-243.
42. Yacoby I., Shamis M., Bar H., Shabat D., Benhar I. Targeting antibacterial agents by using drug-carrying filamentous bacteriophages. Antimicrob Agents Chemother 2006, 50:2087-2097.
43. Rakonjac J., Bennett N.J., Spagnuolo J., Gagic D., Russel M. Filamentous bacteriophage: biology, phage display and nanotechnology applications. Curr Issues Mol Biol 2011, 13:51-76.
44. Nicastro J., Sheldon K., Slavcev R.A. Bacteriophage lambda display systems: developments and applications. Appl Microbiol Biotechnol 2014, 98:2853-2866.
45. Huang J.X., Bishop-Hurley S.L., Cooper M.A. Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. Antimicrob Agents Chemother 2012, 56:4569-4582.
46. Mullen L.M., Nair S.P., Ward J.M., Rycroft A.N., Henderson B. Phage display in the study of infectious diseases. Trends Microbiol 2006, 14:141-147.
47. Bratkovič T. Progress in phage display: evolution of the technique and its applications. Cell Mol Life Sci 2009, 67:749-767.
48. Smith G.P., Petrenko V.A. Phage display. Chem Rev 1997, 97:391-410.
49. Hershey A.D., Chase M. Independent functions of viral protein and nucleic acid in growth of bacteriophage. J Gen Physiol 1952, 36:39-56.
50. Luria S.E., Delbrück M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943, 28:491-511.
51. Green M.R., Sambrook J. Molecular Cloning: A Laboratory Manual 2012, Cold Spring Harbor Laboratory Press.
52. Noireaux V., Bar-Ziv R., Libchaber A. Principles of cell-free genetic circuit assembly. Proc Natl Acad Sci U S A 2003, 100:12672-12677.
53. Kim J., White K.S., Winfree E. Construction of an in vitro bistable circuit from synthetic transcriptional switches. Mol Syst Biol 2006, 2:68.
54. Kim J., Winfree E. Synthetic in vitro transcriptional oscillators. Mol Syst Biol 2011, 7:465.
55. Temme K., Hill R., Segall-Shapiro T.H., Moser F., Voigt C.A. Modular control of multiple pathways using engineered orthogonal T7 polymerases. Nucleic Acids Res 2012, 40:8773-8781.
56. Shis D.L., Bennett M.R. Library of synthetic transcriptional AND gates built with split T7 RNA polymerase mutants. Proc Natl Acad Sci U S A 2013, 110:5028-5033.
57. An W., Chin J.W. Synthesis of orthogonal transcription-translation networks. Proc Natl Acad Sci U S A 2009, 106:8477-8482.
58. Purcell O., Lu T.K. Synthetic analog and digital circuits for cellular computation and memory. Curr Opin Biotechnol 2014, 29C:146-155.
59. Friedland A.E., Lu T.K., Wang X., Shi D., Church G., Collins J.J. Synthetic gene networks that count. Science 2009, 324:1199-1202.
60. Bonnet J., Subsoontorn P., Endy D. Rewritable digital data storage in live cells via engineered control of recombination directionality. Proc Natl Acad Sci U S A 2012, 109:8884-8889.
61. Murphy K.C. Phage recombinases and their applications. Adv Virus Res 2012, 83:367-414.
62. Datsenko K.A., Wanner B.L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 2000, 97:6640-6645.
63. Husseiny M.I., Hensel M. Rapid method for the construction of Salmonella enterica serovar Typhimurium vaccine carrier strains. Infect Immun 2005, 73:1598-1605.
64. Beloin C., Deighan P., Doyle M., Dorman C.J. Shigella flexneri 2a strain 2457T expresses three members of the H-NS-like protein family: characterization of the Sfh protein. Mol Genet Genomics 2003, 270:66-77.
65. Yamamoto S., Izumiya H., Morita M., Arakawa E., Watanabe H. Application of lambda Red recombination system to Vibrio cholerae genetics: simple methods for inactivation and modification of chromosomal genes. Gene 2009, 438:57-64.
66. Derbise A., Lesic B., Dacheux D., Ghigo J.M., Carniel E. A rapid and simple method for inactivating chromosomal genes in Yersinia. FEMS Immunol Med Microbiol 2003, 38:113-116.
67. Lesic B., Rahme L.G. Use of the lambda Red recombinase system to rapidly generate mutants in Pseudomonas aeruginosa. BMC Mol Biol 2008, 9:20.
68. Enyeart P.J., Chirieleison S.M., Dao M.N., Perutka J., Quandt E.M., Yao J., Whitt J.T., Keatinge-Clay A.T., Lambowitz A.M., Ellington A.D. Generalized bacterial genome editing using mobile group II introns and Cre-lox. Mol Syst Biol 2013, 9:685.
69. Langer S.J., Ghafoori A.P., Byrd M., Leinwand L. A genetic screen identifies novel non-compatible loxP sites. Nucleic Acids Res 2002, 30:3067-3077.
70. Wang H.H., Isaacs F.J., Carr P.A., Sun Z.Z., Xu G., Forest C.R., Church G.M. Programming cells by multiplex genome engineering and accelerated evolution. Nature 2009, 460:894-898.
71. Isaacs F.J., Carr P.A., Wang H.H., Lajoie M.J., Sterling B., Kraal L., Tolonen A.C., Gianoulis T.A., Goodman D.B., Reppas N.B., et al. Precise manipulation of chromosomes in vivo enables genome-wide codon replacement. Science 2011, 333:348-353.
72. Lajoie M.J., Rovner A.J., Goodman D.B., Aerni H.-R., Haimovich A.D., Kuznetsov G., Mercer J.A., Wang H.H., Carr P.A., Mosberg J.A., et al. Genomically recoded organisms expand biological functions. Science 2013, 342:357-360.
73. Esvelt K.M., Carlson J.C., Liu D.R. A system for the continuous directed evolution of biomolecules. Nature 2011, 472:499-503.
74. Dickinson B.C., Leconte A.M., Allen B., Esvelt K.M., Liu D.R. Experimental interrogation of the path dependence and stochasticity of protein evolution using phage-assisted continuous evolution. Proc Natl Acad Sci U S A 2013, 110:9007-9012.
75. Leconte A.M., Dickinson B.C., Yang D.D., Chen I.A., Allen B., Liu D.R. A population-based experimental model for protein evolution: effects of mutation rate and selection stringency on evolutionary outcomes. Biochemistry 2013, 52:1490-1499.
76. Lu T.K., Collins J.J. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 2007, 104:11197-11202.
77. Bertani G., Weigle J.J. Host controlled variation in bacterial viruses. J Bacteriol 1953, 65:113-121.
78. Tock M.R., Dryden D.T.F. The biology of restriction and anti-restriction. Curr Opin Microbiol 2005, 8:466-472.
79. Barrangou R., Fremaux C., Deveau H., Richards M., Boyaval P., Moineau S., Romero D.A., Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007, 315:1709-1712.
80. Bull J.J., Vegge C.S., Schmerer M., Chaudhry W.N., Levin B.R. Phenotypic resistance and the dynamics of bacterial escape from phage control. PLoS ONE 2014, 9:e94690.
81. Manning P.A., Puspurs A., Reeves P. Outer membrane of Escherichia coli K-12: isolation of mutants with altered protein 3A by using host range mutants of bacteriophage K3. J Bacteriol 1976, 127:1080-1084.
82. Labrie S.J., Samson J.E., Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol 2010, 8:317-327.
83. Levin B.R., Bull J.J. Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2004, 2:166-173.
84. Westwater C., Kasman L.M., Schofield D.A., Werner P.A., Dolan J.W., Schmidt M.G., Norris J.S. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 2003, 47:1301-1307.
85. Hagens S., Bläsi U. Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett Appl Microbiol 2003, 37:318-323.
86. Hagens S., Habel A., von Ahsen U., von Gabain A., Bläsi U. Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 2004, 48:3817-3822.
87. Moradpour Z., Sepehrizadeh Z., Rahbarizadeh F., Ghasemian A., Yazdi M.T., Shahverdi A.R. Genetically engineered phage harbouring the lethal catabolite gene activator protein gene with an inducer-independent promoter for biocontrol of Escherichia coli. FEMS Microbiol Lett 2009, 296:67-71.
88. Fairhead H. SASP gene delivery: a novel antibacterial approach. Drug News Perspect 2009, 22:197-203.
89. Edgar R., Friedman N., Molshanski-Mor S., Qimron U. Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl Environ Microbiol 2012, 78:744-751.
90. Lu T.K., Collins J.J. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A 2009, 106:4629-4634.
91. Henn M.R., Sullivan M.B., Stange-Thomann N., Osburne M.S., Berlin A.M., Kelly L., Yandava C., Kodira C., Zeng Q., Weiand M., et al. Analysis of high-throughput sequencing and annotation strategies for phage genomes. PLoS ONE 2010, 5:e9083.
92. Reyes A., Semenkovich N.P., Whiteson K., Rohwer F., Gordon J.I. Going viral: next-generation sequencing applied to phage populations in the human gut. Nat Rev Microbiol 2012, 10:607-617.
93. Modi S.R., Lee H.H., Spina C.S., Collins J.J. Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. Nature 2013, 499:219-222.
94. Mills S., Shanahan F., Stanton C., Hill C., Coffey A., Ross R.P. Movers and shakers: influence of bacteriophages in shaping the mammalian gut microbiota. Gut Microbes 2013, 4:4-16.
95. Liu J., Dehbi M., Moeck G., Arhin F., Bauda P., Bergeron D., Callejo M., Ferretti V., Ha N., Kwan T., et al. Antimicrobial drug discovery through bacteriophage genomics. Nat Biotechnol 2004, 22:185-191.
96. Walsh C. Antibiotics: Actions, Origins, Resistance 2003, ASM Press.
97. Pastagia M., Schuch R., Fischetti V.A., Huang D.B. Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol 2013, 62:1506-1516.
98. Schmitz J.E., Schuch R., Fischetti V.A. Identifying active phage lysins through functional viral metagenomics. Appl Environ Microbiol 2010, 76:7181-7187.
99. Schuch R., Pelzek A.J., Raz A., Euler C.W., Ryan P.A., Winer B.Y., Farnsworth A., Bhaskaran S.S., Stebbins C.E., Xu Y., et al. Use of a bacteriophage lysin to identify a novel target for antimicrobial development. PLoS ONE 2013, 8:e60754.
100. Fischetti V.A. Exploiting what phage have evolved to control Gram-positive pathogens. Bacteriophage 2011, 1:188-194.
101. Lukacik P., Barnard T.J., Keller P.W., Chaturvedi K.S., Seddiki N., Fairman J.W., Noinaj N., Kirby T.L., Henderson J.P., Steven A.C., et al. Structural engineering of a phage lysin that targets Gram-negative pathogens. Proc Natl Acad Sci U S A 2012, 109:9857-9862.
102. Patzer S.I., Albrecht R., Braun V., Zeth K. Structural and mechanistic studies of pesticin, a bacterial homolog of phage lysozymes. J Biol Chem 2012, 287:23381-23396.
103. Smartt A.E., Ripp S. Bacteriophage reporter technology for sensing and detecting microbial targets. Anal Bioanal Chem 2011, 400:991-1007.
104. Schofield D.A., Sharp N.J., Westwater C. Phage-based platforms for the clinical detection of human bacterial pathogens. Bacteriophage 2012, 2:105-283.
105. Lu T.K., Bowers J., Koeris M.S. Advancing bacteriophage-based microbial diagnostics with synthetic biology. Trends Biotechnol 2013, 31:325-327.
106. Singh A., Poshtiban S., Evoy S. Recent advances in bacteriophage based biosensors for food-borne pathogen detection. Sensors (Basel) 2013, 13:1763-1786.
107. Tawil N., Sacher E., Mandeville R., Meunier M. Bacteriophages: biosensing tools for multi-drug resistant pathogens. Analyst 2014, 139:1224-1236.
108. Velusamy V., Arshak K., Korostynska O., Oliwa K., Adley C. An overview of foodborne pathogen detection: in the perspective of biosensors. Biotechnol Adv 2010, 28:232-254.
109. Smartt A.E., Xu T., Jegier P., Carswell J.J., Blount S.A., Sayler G.S., Ripp S. Pathogen detection using engineered bacteriophages. Anal Bioanal Chem 2012, 402:3127-3146.
110. Wolber P.K., Green R.L. Detection of bacteria by transduction of ice nucleation genes. Trends Biotechnol 1990, 8:276-279.
111. Edgar R., McKinstry M., Hwang J., Oppenheim A.B., Fekete R.A., Giulian G., Merril C., Nagashima K., Adhya S. High-sensitivity bacterial detection using biotin-tagged phage and quantum-dot nanocomplexes. Proc Natl Acad Sci U S A 2006, 103:4841-4845.
112. Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337:816-821.
113. Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., Norville J.E., Church G.M. RNA-guided human genome engineering via Cas9. Science 2013, 339:823-826.
114. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-823.
115. Hwang W.Y., Fu Y., Reyon D., Maeder M.L., Tsai S.Q., Sander J.D., Peterson R.T., Yeh J.R., Joung J.K. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 2013, 31:227-229.
116. Cho S.W., Kim S., Kim J.M., Kim J.-S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 2013, 31:230-232.
117. Jiang W., Bikard D., Cox D., Zhang F., Marraffini L.A. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 2013, 31:233-239.
118. Mali P., Esvelt K.M., Church G.M. Cas9 as a versatile tool for engineering biology. Nat Methods 2013, 10:957-963.
119. Kiro R., Shitrit D., Qimron U. Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system. RNA Biol 2014, 11:1-3.
120. Gibson D.G., Young L., Chuang R., Venter J.C., Hutchison C.A., Smith H.O. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 2009, 6:343-345.
121. Lu TK, Koeris MS, Chevalier BS, Holder JW, McKenzie GJ, Brownell DR: Recombinant phage and methods 2013. US 13/627,060.
122. Jaschke P.R., Lieberman E.K., Rodriguez J., Sierra A., Endy D. A fully decompressed synthetic bacteriophage øX174 genome assembled and archived in yeast. Virology 2012, 434:278-284.
123. Smith H.O., Hutchison C.A., Pfannkoch C., Venter J.C. Generating a synthetic genome by whole genome assembly: phiX174 bacteriophage from synthetic oligonucleotides. Proc Natl Acad Sci U S A 2003, 100:15440-15445.
124. Gibson D.G., Glass J.I., Lartigue C., Noskov V.N., Chuang R.-Y., Algire M.A., Benders G.A., Montague M.G., Ma L., Moodie M.M., et al. Creation of a bacterial cell controlled by a chemically synthesized genome. Science 2010, 329:52-56.
125. Sleight S.C., Bartley B.A., Lieviant J.A., Sauro H.M. Designing and engineering evolutionary robust genetic circuits. J Biol Eng 2010, 4:12.
126. Chan L.Y., Kosuri S., Endy D. Refactoring bacteriophage T7. Mol Syst Biol 2005, 1:2005.0018.
127. Springman R., Molineux I.J., Duong C., Bull R.J., Bull J.J. Evolutionary stability of a refactored phage genome. ACS Synth Biol 2012, 1:425-430.
128. Gladstone E.G., Molineux I.J., Bull J.J. Evolutionary principles and synthetic biology: avoiding a molecular tragedy of the commons with an engineered phage. J Biol Eng 2012, 6:13.